SCHEDULE OF DEFERRED TAX ASSETS (Details) - USD ($) |
Mar. 31, 2025 |
Mar. 31, 2024 |
|---|---|---|
| Income Tax Disclosure [Abstract] | ||
| Net operating losses carryforwards | $ 3,569,742 | $ 2,689,073 |
| Excess research and development expenses | 85,866 | 90,212 |
| Less: allowance on deferred tax assets | (3,655,608) | (2,779,285) |
| Deferred tax assets |
| X | ||||||||||
- Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|